ClinicalTrials.gg

Program

Cetirizine

Also written as “Cetirizine (Zyrtec)”, “AC-170 0.24%” and “Ceterizine”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Hypersensitivity · Urticaria · Conjunctivitis, Allergic · Rhinitis, Allergic, led by 12 companies.

Furthest: phase 4, since Apr 7, 201131 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aciex Therapeutics70 open or runningphase 3since Apr 7, 2011Apr 7, 2011none ahead
GlaxoSmithKline50 open or runningphase 4since Aug 1, 2013Jun 19, 2007none ahead
JDP Therapeutics30 open or runningphase 3since Dec 18, 2013Dec 18, 2013none ahead
Johnson & Johnson30 open or runningphase 4since Sep 30, 2016Mar 23, 2011none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Feb 4, 2010Feb 4, 2010none ahead
Novartis20 open or runningphase 1since Apr 13, 2009Apr 13, 2009none ahead
Sun Pharmaceutical Industries20 open or runningno phasesince Oct 17, 2008Oct 17, 2008none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Lunan Pharmaceutical Group11 open or runningphase 3since Feb 6, 2025Feb 6, 2025none ahead
nicox-ophthalmics-inc10 open or runningphase 3since Apr 20, 2016Apr 20, 2016none ahead
tersera-therapeutics-llc10 open or runningphase 2since Dec 3, 2019Dec 3, 2019none ahead

Also a collaborator on its studies: algorithme-pharma-inc, ORA, Pfizer and ohm-laboratories-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Jun 19, 2007.

  1. Mar 8, 2012Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01551056 · 91 enrolled · United States
  2. Sep 12, 2012Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01685242 · 100 enrolled · United States
  3. Jun 17, 2013Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01881113 · 101 enrolled · United States
  4. Aug 1, 2013Phase 4 study in RhinitisGlaxoSmithKline · NCT01916226 · 682 enrolled · United States
  5. Dec 18, 2013JDP Therapeutics's first study: phase 1 study in Acute UrticariaNew to JDP TherapeuticsJDP Therapeutics · NCT02024152 · 24 enrolled · Canada
  6. Dec 18, 2013Phase 3 study in UrticariaJDP Therapeutics · NCT02023164 · 36 enrolled · United States, Canada
  7. Apr 29, 2014Phase 3 study in Atopic Disease (Including Allergic Conjunctivitis)Aciex Therapeutics · NCT02132169 · 512 enrolled · United States
  8. Jun 13, 2014Phase 1 study in HealthyAciex Therapeutics · NCT02173249 · 11 enrolled · United States
  9. Apr 20, 2016nicox-ophthalmics-inc's first study: phase 3 study in Healthy SubjectsNew to nicox-ophthalmics-incnicox-ophthalmics-inc · NCT02756624 · 516 enrolled · United States
  10. Sep 30, 2016Phase 4 study in Rhinitis, AllergicJohnson & Johnson · NCT02932774 · 683 enrolled
  11. Oct 14, 2016Phase 3 study in Acute UrticariaJDP Therapeutics · NCT02935699 · 262 enrolled · United States, Canada
  12. Dec 10, 2018Phase 1 study in HypersensitivityJohnson & Johnson · NCT03772158 · 40 enrolled · Canada
  13. Dec 3, 2019tersera-therapeutics-llc's first study: phase 2 study in Oncology Patients Receiving ChemotherapyNew to tersera-therapeutics-llctersera-therapeutics-llc · NCT04189588 · 34 enrolled · United States
  14. Feb 6, 2025Lunan Pharmaceutical Group's first study: phase 3 study in Acute UrticariaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06819774 · 284 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 31 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06819774Acute Urticaria · China3RecruitingLunan Pharmaceutical GroupAug 2025284
NCT04189588Oncology Patients Receiving Chemotherapy · United States2Completedtersera-therapeutics-llcNov 23, 202034
NCT03772158Hypersensitivity · Canada1CompletedJohnson & JohnsonFeb 3, 201940
NCT02935699Acute Urticaria · United States, Canada3CompletedJDP TherapeuticsApr 30, 2018262
NCT02932774Rhinitis, Allergic4CompletedJohnson & JohnsonJul 2001683
NCT02756624Healthy Subjects · United States3Completednicox-ophthalmics-incAug 2016516
NCT02173249Healthy · United States1CompletedAciex TherapeuticsAug 201411
NCT02132169Atopic Disease (Including Allergic Conjunctivitis) · United States3CompletedAciex TherapeuticsOct 2014512
NCT02024152Acute Urticaria · Canada1CompletedJDP TherapeuticsJul 201124
NCT02023164Urticaria · United States, Canada3CompletedJDP TherapeuticsDec 201436
NCT01916226Rhinitis · United States4CompletedGlaxoSmithKlineOct 1, 2013682
NCT01881113Conjunctivitis, Allergic · United States3CompletedAciex TherapeuticsOct 2013101
NCT01685242Conjunctivitis, Allergic · United States3CompletedAciex TherapeuticsNov 2012100
NCT01551056Conjunctivitis, Allergic · United States3CompletedAciex TherapeuticsJun 201291
NCT01495338Normal Ocular Health · United States1CompletedAciex TherapeuticsDec 201160
NCT02447393Dermatitis · Japan1CompletedGlaxoSmithKlineApr 30, 200820
NCT01332188Conjunctivitis, Allergic · United States3CompletedAciex TherapeuticsJun 2011101
NCT01322282Hypersensitivity · Canada1CompletedJohnson & JohnsonMar 201136
NCT01064115Healthy1CompletedDr. Reddy's LaboratoriesJan 200630
NCT01064102Healthy1CompletedDr. Reddy's LaboratoriesJan 200630
NCT00972504Rhinitis, Allergic, Seasonal · Germany2CompletedGlaxoSmithKlineAug 1, 200954
NCT00881634Hypersensitivity1CompletedNovartisJul 200540
NCT00881127Hypersensitivity1CompletedNovartisJul 200540
NCT00864279Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200626
NCT00863902Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200626
NCT00851344Rhinitis, Allergic, Seasonal · Germany2CompletedGlaxoSmithKlineNov 200854
NCT00776139Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200432
NCT00776022Healthy · United States–CompletedSun Pharmaceutical IndustriesApr 200532
NCT00650065Healthy · United States1CompletedViatrisDec 200226
NCT00649857Healthy · United States1CompletedViatrisDec 200218
NCT00490204Rhinitis, Allergic, Perennial · Japan3CompletedGlaxoSmithKlineOct 3, 2007239

How it is read

Names in the registry

  • “Cetirizine”, 6 entries
  • “Cetirizine (Zyrtec)”, 5 entries
  • “AC-170 0.24%”, 5 entries
  • “Ceterizine”, 2 entries
  • “cetirizine”, 2 entries

Codes read as this program: JDP205.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Cetirizine (Aciex Therapeutics): development program | ClinicalTrials.gg